Ocugen (OCGN) Return on Capital Employed (2015 - 2026)
Ocugen (OCGN) reported Return on Capital Employed of 224.57% for Q1 2026, down 12373.0% on a YoY basis from N/an in Q1 2025, and up 1.8% quarter-over-quarter from 228.68% in Q4 2025.
Ocugen (OCGN) Return on Capital Employed (2015 - 2026) Analysis & Trends
Ocugen has reported Return on Capital Employed for 12 years, with the latest figure at 224.57% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 12373.0% year-over-year to 224.57%; the trailing twelve-month figure through Mar 2026 stood at 224.57% (down 12373.0% YoY), and the FY2025 full-year result was 157.54%, down 5205.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 224.57%, up from 228.68% in the prior quarter.
- The five-year high for Return on Capital Employed was 55.93% in Q2 2022, with the low at 228.68% in Q4 2025.
- Historically, Return on Capital Employed has averaged 132.0% across 5 years, with a median of 124.75% in 2023.
- Annual changes were most pronounced in 2025 — Return on Capital Employed soared 4811 bps — and 2026, when it plunged 12373 bps.
- Ocugen's Return on Capital Employed stood at 106.16% in 2022, then fell by 18 bps to 124.75% in 2023, then climbed by 13 bps to 108.21% in 2024, then slumped by 111 bps to 228.68% in 2025, then gained by 2 bps to 224.57% in 2026.
- The last three Return on Capital Employed figures came in at 224.57% (Q1 2026), 228.68% (Q4 2025), and 169.61% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | -224.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -224.57% |
| Dec 31, 2025 | -228.68% |
| Sep 30, 2025 | -169.61% |
| Jun 30, 2025 | -134.97% |
| Mar 31, 2025 | -100.84% |
| Dec 31, 2024 | -108.21% |
| Sep 30, 2024 | -147.82% |
| Jun 30, 2024 | -183.08% |
| Mar 31, 2024 | -141.76% |
| Dec 31, 2023 | -124.75% |
| Sep 30, 2023 | -124.57% |
| Jun 30, 2023 | -132.14% |
| Mar 31, 2023 | -116.07% |
| Dec 31, 2022 | -106.16% |
| Sep 30, 2022 | -81.39% |
| Jun 30, 2022 | -55.93% |
| Mar 31, 2022 | -63.38% |
| Dec 31, 2021 | -55.78% |
| Sep 30, 2021 | -41.44% |
| Jun 30, 2021 | -55.41% |